Radiopharm Theranostics Advances HER2-Targeted Radiotherapy to Higher Dose in Phase 1 Trial
Event summary
- Radiopharm Theranostics' 177Lu-RAD202 Phase 1 HEAT trial advances to Cohort 4 with 180mCi dose level after positive DSMC recommendation.
- Previous 130mCi dose level announced on April 8, 2026, demonstrated favorable safety profile.
- RAD202 targets HER2-positive advanced solid tumors, with prior diagnostic study showing proof-of-concept in 10 breast cancer patients.
- Trial ongoing at clinical centers across Australia, part of Radiopharm's pipeline of five Phase 1 trials.
The big picture
Radiopharm Theranostics' advancement of its HER2-targeted radiotherapeutic reflects growing industry focus on precision oncology solutions for hard-to-treat solid tumors. The company's multi-pronged clinical strategy positions it among a select group of developers leveraging radiopharmaceuticals to address high-unmet medical needs. Success in this Phase 1 trial could validate the company's platform approach across its five ongoing clinical programs.
What we're watching
- Dose Optimization
- How the 180mCi dose level will impact efficacy and safety outcomes in HER2-positive patients.
- Regulatory Pathway
- Whether accelerated development timelines can be maintained based on current DSMC recommendations.
- Competitive Positioning
- The pace at which Radiopharm can differentiate RAD202 in the crowded HER2-targeted therapy space.